Cidara Therapeutics regains compliance with Nasdaq, avoiding delisting.

From GlobeNewswire: 2024-05-15 16:01:00

Cidara Therapeutics, Inc. announced on May 14, 2024 that it has regained compliance with Nasdaq’s listing requirements, avoiding delisting. The company uses its Cloudbreak® platform to develop drug-Fc conjugate immunotherapies to treat serious diseases. Cidara is headquartered in San Diego, California and focuses on creating single molecule cocktails for patients. For more information, visit www.cidara.com. Investors can contact Brian Ritchie at LifeSci Advisors, while media inquiries can be directed to Michael Fitzhugh at LifeSci Communications.



Read more at GlobeNewswire: Cidara Therapeutics Regains Compliance with Nasdaq